相似文献
1
Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):832-843. doi: 10.1080/14756366.2022.2046567.
2
2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
Bioorg Chem. 2020 Jun;99:103798. doi: 10.1016/j.bioorg.2020.103798. Epub 2020 Mar 29.
3
Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Bioorg Chem. 2021 Nov;116:105325. doi: 10.1016/j.bioorg.2021.105325. Epub 2021 Sep 4.
4
Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2742-2754. doi: 10.1080/14756366.2022.2128797.
5
Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Bioorg Chem. 2019 Jul;88:102944. doi: 10.1016/j.bioorg.2019.102944. Epub 2019 Apr 25.
6
Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR and EGFR inhibitors and apoptosis inducers.
Bioorg Chem. 2018 Oct;80:375-395. doi: 10.1016/j.bioorg.2018.06.017. Epub 2018 Jun 12.
7
Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
Bioorg Chem. 2021 Nov;116:105318. doi: 10.1016/j.bioorg.2021.105318. Epub 2021 Sep 1.
8
New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Bioorg Chem. 2021 Oct;115:105208. doi: 10.1016/j.bioorg.2021.105208. Epub 2021 Jul 26.
9
Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1205-1216. doi: 10.1080/14756366.2021.1933466.
10
Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.
Curr Med Chem. 2024;31(24):3798-3817. doi: 10.2174/0929867330666230626143911.
引用本文的文献
1
Design, synthesis and antitumor activity of 4-indazolylpyrimidine derivatives as EGFR inhibitors.
Mol Divers. 2024 Dec 3. doi: 10.1007/s11030-024-11052-y.
2
Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Molecules. 2024 Apr 3;29(7):1597. doi: 10.3390/molecules29071597.
3
In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.
In Silico Pharmacol. 2023 Aug 9;11(1):20. doi: 10.1007/s40203-023-00157-1. eCollection 2023.
4
Discovery of 4-nitro-3-phenylisoxazole derivatives as potent antibacterial agents derived from the studies of [3 + 2] cycloaddition.
RSC Adv. 2022 Sep 8;12(39):25633-25638. doi: 10.1039/d2ra05009a. eCollection 2022 Sep 5.
5
Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2742-2754. doi: 10.1080/14756366.2022.2128797.
本文引用的文献
1
Targeting Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
Cancer Res. 2021 Oct 15;81(20):5311-5324. doi: 10.1158/0008-5472.CAN-21-1526. Epub 2021 Aug 11.
2
Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.
Environ Int. 2021 Nov;156:106760. doi: 10.1016/j.envint.2021.106760. Epub 2021 Jul 10.
3
Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1205-1216. doi: 10.1080/14756366.2021.1933466.
4
Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):987-999. doi: 10.1080/14756366.2021.1915302.
5
EGFR tyrosine kinase inhibitors for mutation-positive non-small-cell lung cancer: outcomes in Asian populations.
Future Oncol. 2021 Jun;17(18):2395-2408. doi: 10.2217/fon-2021-0195. Epub 2021 Apr 15.
6
Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Bioorg Med Chem Lett. 2021 Jun 1;41:127987. doi: 10.1016/j.bmcl.2021.127987. Epub 2021 Mar 23.
7
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Eur J Med Chem. 2021 Apr 15;216:113312. doi: 10.1016/j.ejmech.2021.113312. Epub 2021 Feb 23.
8
Progress of exosomes in the diagnosis and treatment of lung cancer.
Biomed Pharmacother. 2021 Feb;134:111111. doi: 10.1016/j.biopha.2020.111111. Epub 2020 Dec 24.
9
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
J Thorac Oncol. 2021 May;16(5):764-773. doi: 10.1016/j.jtho.2020.12.002. Epub 2020 Dec 14.
10
Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
ChemMedChem. 2021 Feb 17;16(4):600-620. doi: 10.1002/cmdc.202000658. Epub 2020 Nov 24.
Zotero 插件
